

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Hyderabad-500008.
CONSOLIDATED UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2020

Rupees in Lakhs

Sl.No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-12-2020 UnAudited	30-09-2020 UnAudited	31-12-2019 UnAudited	31-12-2020 UnAudited	31-12-2019 UnAudited	
1	Income						
	(a) Revenue from Operations	1578.73	1138.16	842.69	3250.31	1686.40	2394.09
	(b) Other Income	23.34	29.88	37.70	84.78	92.09	157.60
	(c) Unbilled Revenue	0.00	86.80	-	53.00	-	95.80
	Total Income	1,602.07	1,254.84	880.39	3,388.09	1,778.49	2,647.49
2	Expenses						
	(a) Cost of Material Consumed	87.49	59.13	40.97	157.4	117.73	156.89
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-89.00	-90.00	-	-176.60	-	-70.40
	(d) Employee benefit expense	328.24	312.14	293.17	893.01	750.78	1044.52
	(e) Finance Cost	58.59	71.76	73.85	194.15	203.82	273.13
	(f) Depreciation and Amortisation expense	99.62	99.73	100.10	298.19	298.69	392.05
	(g) Other Expenses	422.17	428.99	310.69	1040.01	785.28	1166.37
	Total Expenses	907.11	881.75	818.78	2,406.16	2,156.30	2,296.256
3	Profit before exceptional items and Tax	694.96	373.09	61.61	981.93	-377.81	-315.07
4	Add(+)/Less(-) Exceptional Items	-	-	-	-	-	739.24
5	Profit/ (Loss) before Tax	694.96	373.09	61.61	981.93	-377.81	-1,054.31
6	Tax Expenses	121.97	-98.49	-23.05	192.17	68.99	195.71
7	Profit(Loss) for the Period from Continuing Operations	572.99	274.60	38.56	789.76	-308.82	-858.60
8	Profit(Loss) from Discontinuing Operations	-	-	-	-	-	-
9	Tax Expenses on discontinuing Operations	-	-	-	-	-	-



Sl No	Particulars	Quarter Ended				Nine Months Ended		Year Ended
		31-12-2020 UnAudited	30-09-2020 UnAudited	31-12-2019 UnAudited	31-12-2020 UnAudited	31-12-2019 UnAudited	31-03-2020 Audited	
10	Profit/(Loss) from Discontinuing Operations after Tax	-	-	-	-	-	-	
11	Profit/(Loss) for the period	572.99	274.60	38.56	789.76	-308.82	-858.60	
12	Other Comprehensive Income							
	A (i) Items that will not be reclassified to profit or loss	-0.28	-1.07	0.98	-0.83	-6.77	-2.43	
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	
13	Total Comprehensive Income for the period	572.71	273.53	39.54	788.93	-315.59	-861.03	
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15	
15	Other equity excluding revaluation reserve						792.14	
16	Earnings per Equity share (for continuing operations)							
	a) Basic (Amount in Rupees)	3.74	1.79	0.26	5.16	-2.06	-5.63	
	b) Diluted (Amount in Rupees)	3.74	1.79	0.26	5.16	-2.06	-5.63	
17	Earnings per Equity share (for discontinued operations)							
	a) Basic (Amount in Rupees)							
	b) Diluted (Amount in Rupees)							
18	Earnings per Equity share (for Continuing & discontinued operations)							
	a) Basic (Amount in Rupees)	3.74	1.79	0.26	5.16	-2.06	-5.63	
	b) Diluted (Amount in Rupees)	3.74	1.79	0.26	5.16	-2.06	-5.63	

Notes to the Consolidated Un Audited Financial Results

- 1 The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015
- 2 The above results have been reviewed by the Audit Committee at its meeting held on 27.01.2021 and approved by the Board of Directors of the Company on the same date. These Results are also subjected to Limited Review by the Company's Statutory Auditors.
- 3 The Group currently has two segments (i) clinical research services and (ii) Information technology services.
- 4 The company has considered the possible effects that may result from the pandemic relating to Covid 19 on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. In developing the assumptions relating to the future possible uncertainties in the global economic conditions, the Company has, at the date of approval of these standalone financial results, used internal and external sources of information, including economic forecasts and estimates from market sources, on the expected future performance of the company. On the basis of evaluation and current indicators of future economic conditions, the Company expects to recover the carrying amounts of the above assets and does not anticipate any impairment to these financial and non-financial assets. However, the impact assessment of Covid-19 is a continuing process, given the uncertainties associated with its nature and duration. The company will continue to monitor any material changes in future economic conditions.
- 5 Figures for the previous periods have been rearranged wherever necessary.
- 6 The above consolidated financial results include the Un Audited financial results of the wholly owned subsidiaries, M/s Enhops Solutions Pvt Ltd & Enhops Inc.

Place:Hyderabad
Date: 27.01.2021



SEGMENT-WISE REVENUE RESULTS & CAPITAL EMPLOYED (Consolidated Unaudited)
 UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2020

Particulars	Quarter Ended						Year Ended
	31-12-2020		30-09-2020		31-12-2019		
	UnAudited	Audited	UnAudited	Audited	UnAudited	Audited	
SEGMENT REVENUE: (Net Sales/ Income from Operations)							
a) Clinical Research Services	1,465.64		1,113.15		763.87		2,308.84
b) Information Technology Services	136.43		141.69		116.52		338.65
Total:	1,602.07		1,254.84		880.39		2,647.49
LESS: Inter Segment revenue	-		-		-		-
Net Sales/ income from Operations.	1,602.07		1,254.84		880.39		2,647.49
SEGMENT RESULTS : PROFIT / (LOSS) BEFORE TAX AND INTEREST							
a) Clinical Research Services	763.28		424.62		131.66		-10.96
b) Information Technology Services	(9.73)		20.23		3.80		-30.98
Total:	753.55		444.85		135.46		-41.94
LESS:							
i) Interest	58.59		71.76		73.85		273.13
ii) Other Un-Allocable Expenditure	-		-		-		-
iii) Un-Allocable Income	-		-		-		-
TOTAL PROFIT /-(LOSS) BEFORE TAX	694.96		373.09		61.61		-315.07

Place:Hyderabad
Date:27.01.2021

for Jeevan Scientific Technology Limited
On behalf of the Board of Directors
K. Krishna Kishore
K. Krishna Kishore
Vice Chairman & Managing Director

